ArtiSential® for Rectal Cancer Surgery - Trial NCT06236282
Access comprehensive clinical trial information for NCT06236282 through Pure Global AI's free database. This phase not specified trial is sponsored by Seoul National University Hospital and is currently Completed. The study focuses on Rectal Cancer. Target enrollment is 93 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Seoul National University Hospital
Timeline & Enrollment
N/A
May 01, 2012
Mar 31, 2023
Primary Outcome
Operation time
Summary
This study aimed to assess efficacy of ArtiSential® in reducing laparoscopic rectal cancer
 surgery duration. We retrospectively reviewed the data of patients who underwent laparoscopic
 low or ultralow anterior resection for primary mid-to-low rectal cancer, performed by a
 single surgeon in 2012-2022. Patients were divided into groups, use group vs. non-use group,
 based on the use or non-use of the ArtiSential®. The total mesorectal excision quality and
 resection margin status did not differ between the groups. ArtiSential® reduced operative
 time without impairing surgical quality or oncologic outcomes.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06236282
Device Trial